PROJECT SUMMARY

Project name

Improved diagnostics for visceral leishmaniasis: a prerequisite for elimination

Project short-name

VIP-CARE

AMU project code

EXT/BEL/TH03/CMHS/04/2017

Project phase

I

Partner countries

Universiteit Antwerpen, Flemish Interuniversity Council (VLIR), Belgium

AMU project coordinating office

College of Medicine and Health Sciences

Project type

Research

Project implementation location

Jinka

Target communities

Visceral Leishmaniasis patients

Project coordinator

Dr Tamiru Shibiru

Principal investigator

Dr Tamiru Shibiru and Prof Nicole Berens-Riha

Co-investigators

Mr Dagmawie Tadesse. Prof Johan van Griensven

Total project budget (Euro)

69,718

Project start

1-Sep-23

Project end

31-Aug-25

Financial reporting period

Quarterly

Project finance management office

CMHS finance & budget admin

Progress reporting period

quarterly

Contact person (name and e-mail)

Dr Tamiru Shibiru; This email address is being protected from spambots. You need JavaScript enabled to view it.

PROJECT DESCRIPTION

Visceral leishmaniasis (VL) is among the deadliest neglected tropical diseases worldwide affecting the most impoverished populations. East-African countries accounted for 57% of the VL global burden in 2020. The WHO recently launched a VL elimination plan for East-Africa, with early detection and treatment of VL cases as the backbone to reduce transmission and VL burden. However, due to gaps in diagnostics and inaccessible healthcare the official numbers are just the tip of the iceberg and many patients remain untreated. Molecular diagnostics are promoted but their implementation in resource-constrained setting is very limited. We aim to ameliorate the research capacities and multidisciplinary collaboration of clinical, laboratory and anthropological researchers at Arba Minch University (AMU) and Jinka Hospital in southern Ethiopia to support independent and gender-equal research. Training on molecular techniques, good laboratory and clinical practice, interpretation and communication of results, evidence-based medicine and findings of the study will be organized at AMU and other health facilities. Trainees will train the next generation. In line with the elimination goals, we will define an improved and less-invasive diagnostic algorithm for VL patients which is acceptable and accessible for all. Therefore, a diagnostic study introducing molecular diagnostic in combination with a qualitative study with in-depth interviews of different stakeholders will be conducted. By investing in multistakeholder engagement though a community of practice, including patients, healthcare workers, researchers, policy makers and NGOs, we ensure uptake of research findings into policy and practice.